4
Changes in Ownership
Xenon Pharmaceuticals Inc. Filed Acc 0001193125-25-227202
PRESIDENT, CEO & INTERIM CFO sold 25,000 shares at $40.16 ($1,004,000)
- PRESIDENT, CEO & INTERIM CFO acquired 25,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
MORTIMER IAN · PRESIDENT, CEO & INTERIM CFO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-10-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +25,000 | $7.69 | $192,250 | 56,302 | D |
| 2025-10-01 | Sale : show line 2 in the form 10b5-1 | −25,000 | $40.16 | $1,004,000 | 31,302 | D |
| Open-market sales · 25,000 sh · avg $40.16 · $1,004,000 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-10-01 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −25,000 | 0 | D |
Loading xslF345X05/ownership.xml…